Yes, Polycythemia Vera Should Absolutely Be Considered
A hematocrit persistently above 58% (0.58) warrants immediate evaluation for polycythemia vera (PV), as this exceeds the diagnostic threshold and represents a significant thrombotic risk.
Diagnostic Threshold and Rationale
The WHO diagnostic criteria explicitly incorporate hematocrit values for PV diagnosis, recognizing that many medical centers use hematocrit as their primary tool to evaluate polycythemia 1. While the formal criteria specify hemoglobin thresholds (≥18.5 g/dL in men, ≥16.5 g/dL in women), the guidelines acknowledge that hematocrit greater than the 99th percentile for age, sex, and altitude constitutes the first major criterion 1.
A hematocrit of 58% substantially exceeds normal ranges and falls well above the therapeutic target of <45% used in PV management 2. The evidence specifically notes that aggressive phlebotomy value in hematocrit ranges between 40-55% has been questioned, but your patient at 58% is clearly beyond this range 1.
Clinical Context Supporting PV Consideration
At a hematocrit of 58%, you should actively look for:
- JAK2 V617F mutation (present in >95% of PV cases) 2
- Thrombocytosis (present in 53% of cases) 2
- Leukocytosis (present in 49% of cases) 2
- Splenomegaly (present in 36% of cases) 2
- Symptoms: pruritus (33%), erythromelalgia (5.3%), visual changes (14%), headache 2
The case report 3 illustrates this perfectly: a patient with hematocrit of 58% presented with persistent headaches that resolved completely after hemodilution normalized the hematocrit to 44%.
Diagnostic Algorithm
Step 1: Check JAK2 mutation status and serum erythropoietin level
- If JAK2 V617F positive + subnormal erythropoietin → strongly suggests PV
- Proceed to bone marrow biopsy for confirmation 1
Step 2: Apply WHO criteria
- Diagnosis requires: Both major criteria + 1 minor criterion, OR first major criterion + 2 minor criteria 1
- Major criteria: (1) Elevated hematocrit/hemoglobin, (2) JAK2 mutation
- Minor criteria: (1) Bone marrow panmyelosis, (2) Low erythropoietin, (3) Endogenous erythroid colonies
Step 3: Exclude secondary causes only if JAK2 negative
- Chronic hypoxia, smoking, sleep apnea
- Erythropoietin-secreting tumors
- Medications (androgens, SGLT2 inhibitors) 4
Critical Pitfalls to Avoid
Iron deficiency masking: Iron deficiency can lower hemoglobin/hematocrit levels, potentially masking PV. The guidelines explicitly state you should not be prevented from making a working diagnosis of PV in the presence of iron deficiency, even if formal WHO criteria aren't met 1. For research purposes, demonstrate criteria after iron replacement, but in clinical practice, proceed with PV workup.
Delaying evaluation: At 58% hematocrit, the thrombotic risk is substantial. Arterial thrombosis occurs in 16% and venous thrombosis in 7% of patients at or before diagnosis 2. Splanchnic vein thrombosis is a particularly concerning presentation.
Immediate Management Considerations
While completing the diagnostic workup, recognize that this patient is at high thrombotic risk. The evidence shows that maintaining hematocrit <45% through phlebotomy is the cornerstone of thrombosis prevention 2, 5. All confirmed PV patients should receive low-dose aspirin unless contraindicated 2.
The bottom line: A hematocrit of 58% is not a "wait and see" situation—it demands prompt hematologic evaluation for PV, with JAK2 testing as the initial step.